Jonathan Spicer, MD, PhD, on Perioperative Immunotherapy for Resectable NSCLC: HRQoL Outcomes

September 11, 2025 By The ASCO Post Staff

Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).

Related Content